Privacy issues and the monitoring of sumatriptan in the New Zealand Intensive Medicines Monitoring Programme

Pharmacoepidemiology and Drug Safety

Volumn 10, Issue 7, 2001, Pages 663-667

  Coulter, David M ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Adverse drug reaction reporting systems; Adverse drug reactions; Pharmacoepidemiology; Postmarketing surveillance; Privacy

Indexed keywords

SUMATRIPTAN;

ARTICLE; CLINICAL OBSERVATION; COHORT ANALYSIS; CONFIDENTIALITY; CONTROLLED STUDY; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; INFORMED CONSENT; INTERVIEW; LAW; MAJOR CLINICAL STUDY; MEDICAL ETHICS; MEDICAL INFORMATION SYSTEM; MEDICAL RECORD; NEW ZEALAND; PATIENT ATTITUDE; PATIENT INFORMATION; PRESCRIPTION; PRIORITY JOURNAL; PRIVACY; PROSPECTIVE STUDY; SIDE EFFECT; TELEPHONE;

ATTITUDE; HUMANS; MEDICAL RECORDS; NEW ZEALAND; PHARMACOEPIDEMIOLOGY; PRIVACY; PRODUCT SURVEILLANCE, POSTMARKETING; RESEARCH; SUMATRIPTAN; VASOCONSTRICTOR AGENTS;

EID: 0035569943     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.643     Document Type: Article

References (6)

1. The New Zealand Intensive Medicines Monitoring Programme
2. The New Zealand Intensive Medicines Monitoring Programme in pro-active safety surveillance
3. Health Information Privacy Code 1994
4. A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP)
5. Drug metabolism genotypes and their association with adverse drug reactions in selected populations: A pilot study of methodology